A Double-blind, Randomized Placebo-controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Usage of subcutaneous octreotide to control symptoms associated with carcinoid syndrome, measured as the % of days that subcutaneous octreotide is used as rescue medication based on patient IVRS diary records
16 week double-blind phase of the study
No
Edda Gomez-Panzani, M.D.
Study Director
Ipsen
United States: Food and Drug Administration
2-55-52030-730
NCT00774930
March 2009
December 2015
Name | Location |
---|---|
University of Michigan | Ann Arbor, Michigan 48109-0624 |
University of Mississippi Medical Center | Jackson, Mississippi 39216-4505 |
Eastern Virginia Medical School | Norfolk, Virginia 23507 |
Stanford Cancer Center | Stanford, California 94305-5824 |
University of Pennsylvania | Philadelphia, Pennsylvania 19104 |
Kentuckiana Cancer Institute | Louisville, Kentucky 40202 |
Providence Portland Medical Center | Portland, Oregon 97213-3635 |
UPMC Liver Cancer Center | Pittsburgh, Pennsylvania 15213 |
Louisiana State University Health Science Center | New Orleans, Louisiana 70112 |
David Geffen School of Medicine at UCLA | Los Angeles, California 90095 |
Oregon Health Science University | Portland, Oregon 97239 |
Penn State Milton S. Hershey Medical Center | Hershey, Pennsylvania 17033 |
VA Greater Los Angeles Health Care System | West Los Angeles, California 90073 |
Cedars Sinai Outpatient Cancer Center | West Hollywood, California 90048 |
University of New Mexico Cancer Care Center | Albuquerque, New Mexico 97239 |
Froedtert & Medical College of Wisconsin | Milwaukee, Wisconsin 53226 |